EW - Edwards Lifesciences Corporation

NYSE - Nasdaq Real-time price. Currency in USD
Show:
Income statement
Cash flow
Annual

Balance sheet

All numbers in thousands
Breakdown
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Assets
Current assets
Cash
Cash and cash equivalents
769,000
862,800
1,183,200
1,179,100
Other short-term investments
446,300
604,000
219,400
337,800
Total cash
1,215,300
1,466,800
1,402,600
1,516,900
Net receivables
643,000
582,200
514,600
599,100
Inventory
875,500
726,700
802,300
640,900
Other current assets
195,900
237,100
208,200
168,000
Total current assets
3,095,800
3,180,700
3,091,000
2,984,000
Non-current assets
Property, plant and equipment
Gross property, plant and equipment
1,725,100
1,638,700
1,489,400
1,140,400
Accumulated depreciation
-750,400
-654,600
-598,500
-512,300
Net property, plant and equipment
1,725,100
1,638,700
1,489,400
1,140,400
Equity and other investments
1,239,000
1,834,200
801,600
585,500
Goodwill
1,164,300
1,167,900
1,173,200
1,167,700
Intangible assets
285,200
323,600
331,400
336,500
Other long-term assets
299,100
110,800
119,600
101,800
Total non-current assets
5,196,700
5,321,900
4,146,100
3,504,100
Total assets
8,292,500
8,502,600
7,237,100
6,488,100
Liabilities and stockholders' equity
Liabilities
Current liabilities
Accounts payable
201,900
204,500
196,500
180,400
Accrued liabilities
393,800
360,100
250,600
253,300
Other current liabilities
20,700
3,900
39,300
6,400
Total current liabilities
1,022,400
1,032,300
893,900
902,400
Non-current liabilities
Long-term debt
596,300
595,700
595,000
594,400
Other long-term liabilities
243,700
329,300
438,500
375,800
Total non-current liabilities
1,463,400
1,634,400
1,768,900
1,437,400
Total liabilities
2,485,800
2,666,700
2,662,800
2,339,800
Stockholders' equity
Common stock
646,300
642,000
636,400
218,100
Retained earnings
7,590,000
6,068,100
4,565,000
3,741,600
Accumulated other comprehensive income
-254,900
-157,700
-161,100
-156,000
Total stockholders' equity
5,806,700
5,835,900
4,574,300
4,148,300
Total liabilities and stockholders' equity
8,292,500
8,502,600
7,237,100
6,488,100